{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:19:29Z","timestamp":1791256769751,"version":"4.1.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.ygyno.2011.06.022","type":"journal-article","created":{"date-parts":[[2011,7,13]],"date-time":"2011-07-13T07:24:05Z","timestamp":1310541845000},"page":"19-26","source":"Crossref","is-referenced-by-count":166,"title":["Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study"],"prefix":"10.1016","volume":"123","clinical-trial-number":[{"clinical-trial-number":"nct00429793","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Kian","family":"Behbakht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Sill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Darcy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Mannel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Waggoner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell J.","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy Q.","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew K.","family":"Godwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Katherine","family":"Alpaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2011.06.022_bb0005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2005.05.009","article-title":"Epithelial ovarian cancer: a review of current management","volume":"17","author":"Guppy","year":"2005","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0015","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2006.03.011","article-title":"Systemic therapy for ovarian cancer: current status and new treatments","volume":"33","author":"Ozols","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0020","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/nature04869","article-title":"Ras, PI(3)K and mTOR signalling controls tumour cell growth","volume":"441","author":"Shaw","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0025","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0002-9440(10)61714-2","article-title":"AKT1\/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells","volume":"159","author":"Sun","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0030","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/jcb.10287","article-title":"Frequent activation of AKT2 kinase in human pancreatic carcinomas","volume":"87","author":"Altomare","year":"2002","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0035","doi-asserted-by":"crossref","first-page":"5853","DOI":"10.1038\/sj.onc.1207721","article-title":"AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth","volume":"23","author":"Altomare","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0040","first-page":"3986","article-title":"Akt\/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation","volume":"61","author":"Brognard","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0045","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0092-8674(00)00117-3","article-title":"TOR, a central controller of cell growth","volume":"103","author":"Schmelzle","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0050","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1677\/erc.0.0080249","article-title":"mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer","volume":"8","author":"Yu","year":"2001","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0055","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0060","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S0889-8588(02)00051-5","article-title":"Clinical development of mammalian target of rapamycin inhibitors","volume":"16","author":"Dancey","year":"2002","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0065","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1158\/1078-0432.CCR-06-2770","article-title":"The mTOR inhibitor RAD001 inhibits the proliferation of p53-deficient human ovarian cancer cells, enhances the efficacy of cisplatin in vitro, and prolongs survival in an in vivo ovarian cancer model","volume":"13","author":"Mabuchi","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0070","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1158\/1078-0432.CCR-09-0365","article-title":"mTOR is a promising target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary","volume":"15","author":"Mabuchi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0075","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1756-8722-2-45","article-title":"Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy","volume":"2","author":"Yuan","year":"2009","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0080","first-page":"808","article-title":"Rapamycin and CCI-779","volume":"86","author":"Alexandre","year":"1999","journal-title":"Bull Cancer"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0085","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1158\/1078-0432.CCR-06-0118","article-title":"A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5days every 2weeks to patients with advanced cancer","volume":"12","author":"Hidalgo","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0090","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1200\/JCO.2004.08.116","article-title":"Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer","volume":"22","author":"Raymond","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0095","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cyto.b.20065","article-title":"Comparison of two methods for enumerating circulating tumor cells in carcinoma patients","volume":"68","author":"Balic","year":"2005","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0100","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJMoa040766","article-title":"Circulating tumor cells, disease progression, and survival in metastatic breast cancer","volume":"351","author":"Cristofanilli","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0105","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11864-007-0018-0","article-title":"Integrating circulating tumor cell assays into the management of breast cancer","volume":"8","author":"Dawood","year":"2007","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0110","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1002\/cncr.23852","article-title":"Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?","volume":"113","author":"Dawood","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0115","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1158\/1055-9965.EPI-08-1173","article-title":"Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors","volume":"18","author":"Goodman","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0120","doi-asserted-by":"crossref","first-page":"7053","DOI":"10.1158\/1078-0432.CCR-07-1506","article-title":"Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer","volume":"13","author":"Danila","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0125","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3816\/CCC.2006.n.029","article-title":"Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer","volume":"6","author":"Cohen","year":"2006","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0130","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1200\/JCO.2007.15.8923","article-title":"Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer","volume":"26","author":"Cohen","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0135","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/annonc\/mdn786","article-title":"Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer","volume":"20","author":"Cohen","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0140","doi-asserted-by":"crossref","first-page":"11760","DOI":"10.1073\/pnas.0703875104","article-title":"In vivo quantitation of rare circulating tumor cells by multiphoton intravital flow cytometry","volume":"104","author":"He","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0145","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1002\/ijc.23717","article-title":"Quantitation of circulating tumor cells in blood samples from ovarian and prostate cancer patients using tumor-specific fluorescent ligands","volume":"123","author":"He","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0150","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1158\/1078-0432.CCR-06-2701","article-title":"Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer","volume":"13","author":"Shaffer","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0155","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1593\/neo.08620","article-title":"Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer","volume":"10","author":"de Haas","year":"2008","journal-title":"Neoplasia"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0160","first-page":"104","article-title":"A sample preparation and analysis system for identification of circulating tumor cells","volume":"25","author":"Kagan","year":"2002","journal-title":"J Clin Ligand Assay"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0165","series-title":"State University of New York at Buffalo Department of Biostatistics Technical Report 2006\u20132008","article-title":"A method for utilizing bivariate efficacy outcome measures to screen agents for activity in 2-stage phase II clinical trials","author":"Sill","year":"2008"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0170","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1006\/gyno.1997.4887","article-title":"Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the Gynecologic Oncology Group","volume":"68","author":"Manetta","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0175","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1006\/gyno.1998.5016","article-title":"Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial","volume":"69","author":"Markman","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0180","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00000421-200202000-00009","article-title":"Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study","volume":"25","author":"Plaxe","year":"2002","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0185","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1200\/JCO.2001.19.12.2975","article-title":"Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a Gynecologic Oncology Group study","volume":"19","author":"Fracasso","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0190","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1006\/gyno.2000.5984","article-title":"Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A Gynecologic Oncology Group Study","volume":"79","author":"Hoffman","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0195","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1006\/gyno.1999.5640","article-title":"Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: a Gynecologic Oncology Group trial","volume":"75","author":"Markman","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0200","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1200\/JCO.2003.03.077","article-title":"Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a Gynecologic Group study","volume":"21","author":"Fracasso","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0205","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s002800050786","article-title":"Tomudex (ZD1694, NSC 639186) in platinum-pretreated recurrent epithelial ovarian cancer: a phase II study by the Gynecologic Oncology Group","volume":"42","author":"Muggia","year":"1998","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0210","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1006\/gyno.2001.6182","article-title":"A phase II trial of CI-958 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study","volume":"81","author":"Hoffman","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0215","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1006\/gyno.2000.5755","article-title":"Phase II evaluation of 24-h continuous infusion topotecan in recurrent, potentially platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study","volume":"77","author":"Markman","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0220","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0090-8258(03)00007-6","article-title":"A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study","volume":"89","author":"Hoffman","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0225","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/biomet\/33.3.239","article-title":"The treatment of ties in rank problems","volume":"33","author":"Kendall","year":"1945","journal-title":"Biometrika"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0230","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2307\/1412159","article-title":"The proof and measurement of association between two things","volume":"15","author":"Spearman","year":"1904","journal-title":"Amer J Psychol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0235","series-title":"Statistical Methods for Research Workers","first-page":"1970","author":"Fisher","year":"1934"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0240","doi-asserted-by":"crossref","first-page":"427","DOI":"10.2307\/2288652","article-title":"A network algorithm for performing Fisher's Exact test in r\u00d7c contingency tables","volume":"78","author":"Mehta","year":"1983","journal-title":"J Amer Stat Assn"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0245","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2307\/2281868","article-title":"Nonparemetric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"Am J Statis Assn"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0250","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0255","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11864-009-0100-x","article-title":"Current status on biologic therapies in the treatment of epithelial ovarian cancer","volume":"10","author":"Han","year":"2009","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0260","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1517\/14656560903120907","article-title":"Antiangiogenic drugs in ovarian cancer","volume":"10","author":"Markman","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0265","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0270","doi-asserted-by":"crossref","first-page":"7s","DOI":"10.1200\/jco.2010.28.18_suppl.lba1","article-title":"Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC) or fallopian tube cancer (FTC): a Gynecologic Oncology Group study","volume":"28","author":"Burger","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0275","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2009.07.023","article-title":"A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study","volume":"115","author":"Aghajanian","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2011.06.022_bb0280","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.2003.10.104","article-title":"Evaluation of monoclonal humanized anti-HER2 antibody (Trastuzumab) in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group","volume":"21","author":"Bookman","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0285","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-05-0462","article-title":"Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group study","volume":"11","author":"Schilder","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0290","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1200\/JCO.2007.14.3420","article-title":"Phase II evaluation of imatinib methylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study","volume":"26","author":"Schilder","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0295","doi-asserted-by":"crossref","first-page":"15S","DOI":"10.1200\/jco.2008.26.15_suppl.5537","article-title":"Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): a Gynecologic Oncology Group (GOG) study","volume":"26","author":"Matei","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0300","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.26.7856","article-title":"Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a Gynecologic Oncology Group trial","volume":"29","author":"Matei","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0305","first-page":"S16","article-title":"A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies","volume":"116","author":"Usha","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0310","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0315","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4137\/CMO.S1590","article-title":"Treatment options in metastatic renal cell carcinoma: focus on mTOR inhibitors","volume":"4","author":"Pal","year":"2010","journal-title":"Clin Med Insights Oncol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0320","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.1212704","article-title":"Upstream and downstream of mTOR","volume":"18","author":"Hay","year":"2004","journal-title":"Genes Dev"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0325","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1182\/blood-2004-03-1153","article-title":"In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model","volume":"104","author":"Frost","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0330","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2174\/156652405774641034","article-title":"Mammalian target of rapamycin as a therapeutic target in leukemia","volume":"5","author":"Giles","year":"2005","journal-title":"Curr Mol Med"},{"issue":"Suppl","key":"10.1016\/j.ygyno.2011.06.022_bb0335","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1053\/j.seminoncol.2009.10.011","article-title":"Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth","volume":"3","author":"Gibbons","year":"2009","journal-title":"Semin Oncol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0340","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1371\/journal.pbio.1000038","article-title":"Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2","volume":"7","author":"Feldman","year":"2009","journal-title":"PLoS Biol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0345","doi-asserted-by":"crossref","first-page":"6232","DOI":"10.1158\/0008-5472.CAN-09-0299","article-title":"Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin","volume":"69","author":"Yu","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0350","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.4161\/cc.8.23.10070","article-title":"Thinking beyond rapamycin","volume":"8","author":"Targeting mTOR globally in cancer","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0355","first-page":"731","article-title":"Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility","volume":"35","author":"Gulati","year":"2009","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0360","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1158\/1535-7163.MCT-08-0254","article-title":"Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin","volume":"8","author":"Frost","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0365","first-page":"179","article-title":"Association of disease progression and poor overall survival with detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer","volume":"13","author":"Bauernhofer","year":"2005","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0370","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ctrv.2008.11.003","article-title":"Detection of circulating tumor cells in bladder cancer patients","volume":"35","author":"Nezos","year":"2009","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/CCLM.2009.009","article-title":"Molecular markers detecting circulating melanoma cells by reverse transcription polymerase chain reaction: methodological pitfalls and clinical relevance","volume":"47","author":"Nezos","year":"2009","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0380","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1056\/NEJMoa0800668","article-title":"Detection of mutations in EGFR in circulating lung-cancer cells","volume":"359","author":"Maheswaran","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0385","first-page":"895","article-title":"Detection of circulating tumor cells from renal carcinoma patients: experiences of a two-center study","volume":"14","author":"Blumke","year":"2005","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0390","doi-asserted-by":"crossref","first-page":"6897","DOI":"10.1158\/1078-0432.CCR-04-0378","article-title":"Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases","volume":"10","author":"Allard","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2011.06.022_bb0395","first-page":"1111","article-title":"Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer","volume":"21","author":"Hayes","year":"2002","journal-title":"Int J Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811004896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811004896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T02:25:06Z","timestamp":1741314306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825811004896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0090825811004896"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2011.06.022","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}